You are now searching through our whole database. To make more specific queries, you can use our menu or go directly to papers, companies, trials, or events.
This double-blind, placebo-controlled crossover trial (n=24) will investigate the effects of low-dose MDMA (25mg or 50mg) on oxytocin levels in patients with arginine vasopressin deficiency (a condition affecting water balance in the body, also known as central diabetes insipidus) and in healthy controls.
This Phase III, double-blind, randomised controlled trial (n=330) will assess the efficacy, safety, and tolerability of a synthetic psilocybin analogue (CYB003) as an adjunctive treatment for major depressive disorder (MDD).
This interventional trial (n=38) will assess the safety, tolerability, pharmacokinetics (how the drug is absorbed and processed by the body), and pharmacodynamics (how the drug affects the body) of SPL028 (a modified form of DMT) when given intravenously (IV) or intramuscularly (IM) in healthy volunteers and participants with major depressive disorder (MDD).
This Phase I trial (n=44) aims to assess the safety, tolerability, and pharmacokinetics (how the drug is absorbed, distributed, and eliminated by the body) of COMP360 (psilocybin) in healthy volunteers. The study also investigates how food intake affects the body’s response to a 25 mg dose and examines the relationship between COMP360 dosage and heart function, specifically the QT interval (a measure of electrical activity in the heart).
This Phase I, open-label trial (n=6) investigates how psilocybin (COMP360; 10mg) is absorbed, distributed, metabolised, and excreted in healthy male volunteers aged 30-55.
In January 2025, psychedelic research saw modest activity, contributing 11 new studies and 183 linked studies. This month's additions include clinical trial results, real-world implementation studies, and analyses that further our understanding of these innovative treatments.
This systematic review and meta-analysis (s=87; 2025) finds esketamine's efficacy as an adjunctive therapy for treatment-resistant depression (TRD) to be modest (effect size 0.15-0.23) and comparable to atypical antipsychotics, with no significant effect on suicidality. The review raises concerns about esketamine's abuse potential and unknown long-term effects. It also highlights regulatory issues, including deaths and emerging suicidality during clinical trials.
This single-arm, Phase I/II pilot trial (n=30) will test psilocybin-assisted psychotherapy (25mg x 2 doses, 4 weeks apart) for treatment-resistant obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD), and anorexia nervosa (AN).
This Phase I crossover trial (n=34) will compare the bioavailability of two ketamine formulations (R-107-H vs R-107-P) in healthy volunteers under fasting conditions.
This open-label, phase II trial (n=20) will investigate the feasibility, safety, and effects of psilocybin-assisted psychotherapy for cancer survivors experiencing depression and/or anxiety.
Psychedelic Database
Find everything on psychedelics as medicine. This page allows you to search through our whole database, from research papers to news articles, and from clinical trials to academic articles.
Next to our databases, don’t forget to check out our reports. The reports bring together the separate pieces of information from our database entries into written reports.
